INCREASING MEDICAL MARIJUANA AND CANNABIDIOL RESEARCH

The White House issued an executive order directing the Attorney General to expedite rescheduling marijuana to Schedule III and instructing the administration to work with Congress on updating the statutory definition and regulatory framework for hemp-derived cannabinoid (CBD) products, including THC-per-serving/container limits and CBD:THC ratios. The order cites HHS/FDA findings (HHS recommended rescheduling in 2023; FDA found credible support for use in pain, anorexia and chemo-induced nausea), notes more than 30,000 practitioners across 43 jurisdictions and over 6 million registered medical marijuana patients, and references a May 2024 DOJ proposed rule that received ~43,000 public comments—changes that could broaden research, regulatory clarity and commercial opportunity for cannabis and CBD firms if implemented.

Analysis

Market structure: Rescheduling to Schedule III materially shifts winners toward U.S.-focused MSOs, CBD consumer brands, and regulated hemp growers because banking access, Section 280E tax relief pathways and prescription-adjacent product channels become achievable—market share should shift ~60/40 toward compliant U.S. operators versus informal/black-market supply over 12–36 months. Incumbent pharma with pain franchises face modest demand erosion (single-digit % annual pain Rx decline initially) but benefit from partnership/licensing opportunities. Cross-asset: improved cashflow for MSOs reduces credit spreads for sector high-yield and could narrow municipal revenue volatility in states with legal cannabis taxes; CAD could weaken modestly on reduced premium for Canadian LPs over U.S. peers.

Risk assessment: Tail risks include a federal court injunction, reversal after the administrative hearing, or Congress imposing restrictive THC limits (per-serving cap) that re-segments markets; any of these can wipe out >50% of speculative market caps. Time horizons: immediate price moves on DOJ/hearing notices (days–weeks), regulatory drafting and banking access over 3–12 months, full commercial and clinical research impacts over 1–3 years. Hidden dependencies: banking rules, IRS/Medicare guidance, and per-serving THC caps will determine margin expansion; supply-side capex can create a multi-year hemp/glut risk similar to 2019.

Trade implications: Favor ETFs and large liquid U.S. MSOs to capture regulatory de-risking while limiting single-name execution risk—target 1–3% position sizing per trade with stop-losses. Use 4–9 month call spreads on MJ (ETFMG MJ) or TLRY to lever a favorable rulemaking outcome while selling OTM calls to fund premium; size such options trades to <1% portfolio. Pair trades: long U.S. MSO Curaleaf (CURLF) 2–3% vs short Canadian LP Canopy Growth (CGC) 1–2% to arbitrate regulatory-territory rerating.

Key Decisions for Investors

• Establish a 1.5–3% portfolio long position in MJ (ETFMG Alternative Harvest ETF, ticker MJ) within 2–6 weeks to capture sector-wide derisking; set a 20% trailing stop and target 40–100% upside in 12–24 months if rescheduling proceeds.
• Initiate a 2% long position in Curaleaf (CURLF) and a 1.5% short in Canopy Growth (CGC) as a pair trade within 30 days; thesis: U.S. MSOs re-rate on banking/280E relief while Canadian LP multiples compress. Close or reassess at +/-30% P&L or upon final DOJ rule outcome.
• Buy 4–9 month call debit spreads on MJ or TLRY equal to 0.5–1% portfolio exposure (buy ATM, sell ~20% OTM) to capture upside from rulemaking noise while capping premium; hedge by selling 1–2% short-dated (30–60 day) OTM calls if IV surges >40%.
• Allocate 0.5–1% to select CBD/hemp consumer names (e.g., Charlotte's Web CWBHF) with strict sell discipline: take profits at +50% and stop at -30% within 6–12 months, conditional on HHS/FDA guidance on per‑serving THC and labeling standards being released within 90 days.